期刊文献+

直肠癌组织中miR-144、ROCK-1 mRNA表达变化及其意义 被引量:2

下载PDF
导出
摘要 目的 观察直肠癌组织中微小RNA-144(miR-144)与Rho相关卷曲螺旋形成蛋白激酶-1(ROCK-1)的表达变化,并探讨其意义。方法 直肠癌患者100例,均接受手术切除治疗,术中留取癌组织及癌旁组织,采用qRT-PCR法检测直肠癌组织及癌旁组织中miR-144、ROCK-1mRNA,分析直肠癌组织中miR-144、ROCK-1mRNA表达的相关性,分析miR-144、ROCK-1mRNA表达与直肠癌患者临床病理参数的关系。结果 直肠癌组织中miR-144、ROCK-1mRNA的相对表达量分别为0.48±0.06、0.96±0.20,癌旁组织中miR-144、ROCK-1mRNA的相对表达量分别为0.98±0.07、0.24±0.12,两者相比,P均<0.05。直肠癌癌组织中miR-144、ROCK-1mRNA表达呈明显负相关(r=-0.683,P=0.002)。miR-144、ROCK-1mRNA表达与直肠癌患者肿瘤分化和肿瘤分期有关(P均<0.05)。结论 直肠癌组织中miR-144呈低表达,ROCK-1mRNA呈高表达,两者可能共同参与直肠癌的发生发展。
出处 《山东医药》 CAS 2019年第24期76-78,共3页 Shandong Medical Journal
基金 河北省科技计划项目(162777125) 邢台市科技计划项目(2017ZC085)
  • 相关文献

参考文献7

二级参考文献67

  • 1许岸高,姜泊,钟旭辉,余志金,刘集鸿.广东地区近20年大肠癌临床特征的变化趋势[J].中华医学杂志,2006,86(4):272-275. 被引量:86
  • 2Peter Boyle,Maria Elena Leon.Epidemiology of colorectal cancer[J]. British Medical Bulletin . 2002
  • 3Ahmed A. Abou-Zeid M.D., F.R.C.S.(Edinb.),Wael Khafagy M.D.,Deya M. Marzouk M.D., F.R.C.S.(Edinb.),Ahmed Alaa M.D., F.R.C.S.(Edinb.),I. Mostafa M.D.,M. Aboul Ela M.D..Colorectal Cancer in Egypt[J]. Diseases of the Colon & Rectum . 2002 (9)
  • 4D. MaxwellParkin,FreddieBray,JacquesFerlay,PaolaPisani.Estimating the world cancer burden: Globocan 2000[J]. Int. J. Cancer . 2001 (2)
  • 5International Agency for Research on Cancer.Colorectal cancer estimated incidence,mortality and prevalence worldwide in2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx .
  • 6Centers for Disease Control and Prevention.Colorectal Cancer Rates by Race and Ethnicity. http://www.cdc.gov/cancer/colorectal/statistics/race.htm .
  • 7Tournigand C,Andre T,Achille E,et al.FOLFIRI followed by FOLF-OX6 or the reverse sequence in advanced colorectal cancer:a ran- domized GERCOR study[J].J Clin Oncol,2004,22(2):229-237.
  • 8Van Cutsem E,Kohne CH,Hitre E,et al.Cetuximab and chemother- apy as initial treatment for metastatic colorectal cancer[J].N Engl J Med,2009,360(14):1408-1417.
  • 9Le Cesne A,Van Glabbeke M,Verweij J,et al.Absence of progres- sion as assessed by response evaluation criteria in solid tumors pre- dicts survival in advanced Gl stromal tumors treated with imatinib mesylate:the intergroup EORTC-ISG-AGITG phase III trial[J].J Clin Oncol,2009,27(24):3969-3974.
  • 10Popov I,Jelic S,Radosavfjevid D,et al.The role of stable disease in objective response assessment and its impact on survival in ad- vanced colorectal cancer:is "stable disease" a homogenous re- sponse category[J].Neoplasma,1999,46(2):132-139.

共引文献679

同被引文献15

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部